DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia.

Author(s): Steinherz PG, Meyers PA, Steinherz LJ, Jeha S

Affiliation(s): Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA. steinhep@MSKCC.ORG

Publication date & source: 2007-09, J Pediatr Hematol Oncol., 29(9):656-8.

Publication type: Case Reports

Current treatments for relapsed/refractory leukemias are unable to achieve extended remissions in most patients even with multiagent chemotherapy. Clofarabine is a new nucleoside analog that has demonstrated clinical benefit in phase I-II studies, and is currently being studied in children and adults with leukemias and has been approved for the treatment of children with relapsed or refractory acute lymphocytic leukemia. We report the experience of three adolescents, two with acute lymphocytic leukemia in 3rd relapse and one with relapsed/refractory acute myeloid leukemia, who achieved complete remission with clofarabine. The remissions were sustained with repeated cycles of monotherapy for 47, 59, and 64 weeks, respectively.

Page last updated: 2008-01-02

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017